Skip to main content

Table 1 Demographic and clinical characteristics of the included subjects

From: Texture analysis of T2-weighted cardiovascular magnetic resonance imaging to discriminate between cardiac amyloidosis and hypertrophic cardiomyopathy

  CA (n = 100) HCM (n = 217) P values
Age, years 58.5 ± 10.7 50.7 ± 14.8  < 0.001
Gender, females, n(%) 41 (41%) 101 (46.5%) 0.318
BMI, kg/m2 22.0 ± 3.3 24.1 ± 3.5  < 0.001
NYHA III-IV, n(%) 64 (64%) 23 (10.6%)  < 0.001
Hypertension, n(%) 16 (16%) 65 (30%) 0.001
Diabetes, n(%) 9 (9%) 18 (8.3%) 0.263
Dyslipidemia, n(%) 7 (7%) 12 (5.5%) 0.823
Sub-types of HCM
 Asymmetrical/LOVOT 37 168/124  
 Concentric 63 36  
 Mid-ventricular 2  
 Apical 11  
AL, n(%) 93 (93%) /  
NT-proBNP, pg/ml 8.5 ± 1.1 7.0 ± 1.0  < 0.001
Troponin T, pg/ml 4.6 ± 0.7 3.0 ± 0.9  < 0.001
Medications
 Diuretics 68 (68%) 26 (12%)  
 β-blockers 26 (26%) 78 (35.9%)  
 ACEI/ARB 12 (12%) 31 (14.2%)  
Ca2+ blockers 5 (5%) 33 (15.2%)  
 Statin 8 (8%) 22 (10.1%)  
Cardiovascular magnetic resonance
 LV-ESV index, ml 26.6 ± 9.5 23.9 ± 9.2 0.029
 LV-EDV index, ml 49.6 ± 11.4 59.8 ± 13.8  < 0.001
 LVEF, % 46.6 ± 13.0 61.0 ± 7.9  < 0.001
 LV mass index, g/m2 43.3 ± 13.3 45.6 ± 17.5 0.25
 MWT 15.4 (14.5, 17.6) 18.5 (16.2, 21.1)  < 0.001
Presence of main LGE pattern
 Patchy 17 (24.3%) 163 (75%)  
 Transmural 25 (35.7%) 54 (25%)  
 Subendocardial 23 (32.8%)   
 Diffuse 5 (7.2%)   
 LGE extent (g) 55.9 (37.3, 81.3) 10.2 (3.2, 25.2)  < 0.001
 LGE extent (%) 49.4 (37.4, 63.8) 11.4 (4.5, 21.6)  < 0.001
  1. CA: cardiac amyloidosis; HCM: hypertrophic cardiomyopathy; AL: light-chain amyloidosis; ESV: end-systolic volume; EDV: end-diastolic volume; LVEF: left ventricular ejection fraction; MWT: maximal wall thickness; LGE: late gadolinium enhancement